The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most recently, Sherpa et al. [262] showed that CrM (5 grams/day) could augment the antidepressant effects of cognitive behavioral therapy (CBT).”
From Creatine monohydrate supplementation for older adults and clinical populations (2025) · cites this paper as [262]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · cited 12×
“On each research visit, participants were reminded of the study procedures and completed the PHQ-9 and SEQ questionnaires; then, they received a 45-minute CBT session.”
BackgroundMethodInfluentialCipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Cuijpers, P., Noma, H., Karyotaki, E., Vinkers, C. H., Cipriani, A., & Furukawa, T. A. (2020) · World Psychiatry · doi:10.1002/wps.20701 · Cited by 540
Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses
Sarris, J., Murphy, J., Mischoulon, D., Papakostas, G. I., Fava, M., Berk, M., & Ng, C. H. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.15091228 · Cited by 436
Cuijpers, P., Quero, S., Noma, H., Ciharova, M., Miguel, C., Karyotaki, E., Cipriani, A., Cristea, I. A., & Furukawa, T. A. (2021) · World Psychiatry · doi:10.1002/wps.20860 · Cited by 388
Cuijpers, P., Miguel, C., Harrer, M., Plessen, C. Y., Ciharova, M., Ebert, D., & Karyotaki, E. (2023) · World Psychiatry · doi:10.1002/wps.21069 · Cited by 354
Antonio, J., Candow, D. G., Forbes, S. C., Gualano, B., Jagim, A. R., Kreider, R. B., Rawson, E. S., Smith-Ryan, A. E., VanDusseldorp, T. A., Willoughby, D. S., et al. (2021) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-021-00412-w · Cited by 345 · cited 1×
“…8 weeks in duration, so we cannot exclude that longer administrations might lead to a more substantial adverse-event burden, and indeed concerns have been raised regarding chronic use of creatine supplementation, especially for individuals with pre-existing renal disorders (Antonio et al., 2021).”
BackgroundCreatine Supplementation and Brain Health
Roschel, H., Gualano, B., Ostojic, S. M., & Rawson, E. S. (2021) · Nutrients · doi:10.3390/nu13020586 · Cited by 174
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136 · cited 1×
“…to adverse events (tolerability), and the proportion of patients experiencing at least one adverse event (safety) reported on a pre-specified Side Effect Questionnaire (SEQ, Supplementary Material, S3) at study endpoint – as per several clinical trials (Cipriani et al. 2018; Kishi et al., 2023).”
Background
Research works printed but not linked: 27
- Allen, 2010, Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner, Neuropsychopharmacol. (New York, N.Y.), 35, 534
- Allen, 2012, Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats, Pharmacol., Biochem. Behav., 101, 588, 10.1016/j.pbb.2012.03.005 · DOI
- Allen, 2015, Chronic high-dose creatine has opposing effects on depression-related gene expression and behavior in intact and sex hormone-treated gonadectomized male and female rats, Pharmacol., Biochem. Behav., 130, 22, 10.1016/j.pbb.2014.12.014 · DOI
- Buerkner, 2017, Brms: an R package for bayesian multilevel models using stan, J. Stat. Softw., 80, 1
- Candow, 2023, Heads up” for creatine supplementation and its potential applications for brain health and function, Sports Med. (Auckland), 1
- Chevance, 2022, Important adverse events to be evaluated in antidepressant trials and meta-analyses in depression: a large international preference study including patients and healthcare professionals, Evid. Based Ment. Health, 25, e41, 10.1136/ebmental-2021-300418 · DOI
- Croatto, 2023, The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: an umbrella review of the evidence from randomised controlled trials, Mol. Psychiatry, 28, 369, 10.1038/s41380-022-01770-w · DOI · Paper page
- Cunha, 2012, Antidepressant-like effect of creatine in mice involves dopaminergic activation, J. Psychopharmacol. (Oxford), 26, 1489, 10.1177/0269881112447989 · DOI
- Cunha, 2013, Evidence for the involvement of 5-HT1A receptor in the acute antidepressant-like effect of creatine in mice, Brain Res. Bull., 95, 61, 10.1016/j.brainresbull.2013.01.005 · DOI
- Faulkner, 2021, Relationship between depression, prefrontal creatine and grey matter volume, J. Psychopharmacol. (Oxford), 35, 1464, 10.1177/02698811211050550 · DOI
- Forbes, 2022, Effects of creatine supplementation on brain function and health, Nutrients, 14, 921, 10.3390/nu14050921 · DOI · Paper page
- Ghaemian, 2020, Therapy discontinuation in a primary care psychological service: why patients drop out, Cognit. Behav. Therap., 13, e25, 10.1017/S1754470X20000240 · DOI · Paper page
- Kanekar, 2021, Sex-based impact of creatine supplementation on depressive symptoms, brain serotonin and SSRI efficacy in an animal model of treatment-resistant depression, Int. J. Mol. Sci., 22, 8195, 10.3390/ijms22158195 · DOI
- Kious, 2017, An open-label pilot study of combined augmentation with creatine monohydrate and 5-hydroxytryptophan for selective serotonin reuptake inhibitor- or serotonin-norepinephrine reuptake inhibitor-resistant depression in adult women, J. Clin. Psychopharmacol., 37, 578, 10.1097/JCP.0000000000000754 · DOI · Paper page
- Kondo, 2011, Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study, J Affect Disord, 135, 354, 10.1016/j.jad.2011.07.010 · DOI · Paper page
- Kondo, 2016, Creatine target engagement with brain bioenergetics: a dose-ranging phosphorus-31 magnetic resonance spectroscopy study of adolescent females with SSRI-resistant depression, Amino Acids, 48, 1941, 10.1007/s00726-016-2194-3 · DOI · Paper page
- Lyoo, 2003, Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate, Psychiatry Res., 123, 87, 10.1016/S0925-4927(03)00046-5 · DOI · Paper page
- Lyoo, 2012, A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder, Am. J. Psychiatry, 169, 937, 10.1176/appi.ajp.2012.12010009 · DOI · Paper page
- Nemets, 2013, A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression, Int. Clin. Psychopharmacol., 28, 127, 10.1097/YIC.0b013e32835ff20f · DOI
- Pazini, 2019, The possible beneficial effects of creatine for the management of depression, Prog. Neuropsychopharmacol. Biol. Psychiatry, 89, 193, 10.1016/j.pnpbp.2018.08.029 · DOI
- Pazini, 2020, mTORC1-dependent signaling pathway underlies the rapid effect of creatine and ketamine in the novelty-suppressed feeding test, Chem. Biol. Interact., 332, 10.1016/j.cbi.2020.109281 · DOI
- Raman, 2021, Impact on health and provision of healthcare services during the COVID-19 lockdown in india: a multicentre cross-sectional study, BMJ Open, 11, 10.1136/bmjopen-2020-043590 · DOI
- Toniolo, 2018, A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression, J. Neural Transm., 125, 247, 10.1007/s00702-017-1817-5 · DOI · Paper page
- van Buuren, 2011, Mice: multivariate imputation by chained equations in R, J Stat Softw, 45, 1
- Wyss, 2000, Creatine and creatinine metabolism, Physiol. Rev., 80, 1107, 10.1152/physrev.2000.80.3.1107 · DOI · Paper page
- Yoon, 2016, Effects of creatine monohydrate augmentation on brain metabolic and network outcome measures in women with major depressive disorder, Biol. Psychiatry., 80, 439, 10.1016/j.biopsych.2015.11.027 · DOI · Paper page
- Yuan, 2022, Neural effects of cognitive behavioral therapy in psychiatric disorders: a systematic review and activation likelihood estimation meta-analysis, Front. Psychol.
Cited by
Creatine monohydrate supplementation for older adults and clinical populations
Candow, D. G., Ostojic, S. M., Chilibeck, P. D., Longobardi, I., Gualano, B., Tarnopolsky, M. A., Wallimann, T., Moriarty, T., Kreider, R. B., Forbes, S. C., et al. (2025) · Journal of the International Society of Sports Nutrition · doi:10.1080/15502783.2025.2534130 · Cited by 43
Metadata
- Authors
- Sherpa, N. N., De Giorgi, R., Ostinelli, E. G., Choudhury, A., Dolma, T., & Dorjee, S.
- Venue
- European Neuropsychopharmacology
- Publisher
- Elsevier BV
- Published
- 2025-01
- Volume
- 90
- Pages
- 28-35
- ISSN
- 0924-977X
- Cited by
- 22
- References
- 21
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area. https://app.cochat.ai/papers/10.1016/j.euroneuro.2024.10.004
- The paper
- Sherpa, N. N., De Giorgi, R., Ostinelli, E. G., Choudhury, A., Dolma, T., & Dorjee, S. (2025). Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural therapy in depression: An 8-week pilot, double-blind, randomised, placebo-controlled feasibility and exploratory trial in an under-resourced area. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2024.10.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
